Ted – Sorry this took a bit longer to find and organize than I thought... hope it's useful to you.
The following post was offered in 2004 which is described as a prelude to CR 24 on the fibrosis subject, titled:
Cardiac Fibrotic Remodeling – The Role of Fibrosis in LAF (http://www.afibbers.org/conference/session24.pdf)
Since this posting 12 years ago, we’ve referenced the topic of fibrosis periodically and referred new readers to CR 24 and in 2012, an extensive update was posted as CR 75. Both 24 and 75 should be considered essential reading and should always be read with the understanding of the consequences of the inflammatory process that leads to fibrosis.
LAF and Cardiac Fibrosis - CR 75 [
www.afibbers.org]
Another post was offered on the findings of William J Rowe, MD, and magnesium deficiency in the endurance runner Sy Mah. Reference link: [
www.femsinspace.com] Dr. Rowe is well known for his research to help astronauts in space flight – maintaining their health, watching out for the detrimental effects such as advanced aging in space travel and as he indicates, it gives an important preview of what we might expect (eventually over time) in the aging body here on Earth. What’s useful is his emphasis on the importance of magnesium in the role of fibrosis and since magnesium is an antioxidant, correcting Mg deficiencies is equally important in controlling vicious cycles with catecholamines and (in turn) …. ischemia.
At this point in time, I remain disappointed that fibrosis presence or management thereof, is not emphasized or investigated when new afibbers seek medical attention. There is no mention of measuring intracellular stores of magnesium as a means of either helping to prevent arrhythmias or aggressive supplementing with either magnesium or fibrinolytic enzymes as a reversal method. In my 20-year history of consulting and treating for AF which includes three cardiologists, four EPs and three separate ER treatment facilities, the subject of preventing fibrosis formation or reversing it was never mentioned nor was measuring intracellular magnesium status. When I attended a local Atrial Fibrillation Summit sponsored by the Cleveland Clinic in 2004, I sat in on a session with Translational Researcher, David Van Wagoner, PhD, in which he explained his research on the role of fibrosis. That led to more research and the referenced fibrosis studies by Kuhmar & Shivakumar listed at the end of this report.
Understanding at least one cause of cardiac fibrosis formation – such as from intense endurance exercise and the resultant fibrotic response to the constant (and damaging) to free radical oxidative stress is important. With our own ‘poster boy example’ as in GeorgeN’s initial story, one can see that for him, tackling the afib problem with high dosing of magnesium, along with diet and other strategies has paid big dividends in that he was able to reverse the Afib trend and undoubtedly, with time, also the fibrosis or at least enough to lessen conduction interferences. As George states, he’s altered his exercise intensity.
This is an important topic.
Here’s the lead-in to that initial CR 24 post…(followed by other relevant study clips) for your reading enjoyment.
Jackie
Following also are a few links to relevant research reports and findings on cardiac fibrosis from my files and if you check those two Conference Room Sessions, there are other references as well.
2004 Consider this a prelude to the coming update on CR 24 – Cardiac Fibrosis.
Following are a few key points from my ongoing observations found in the literature. .
Specific details will be included in the final report.
Jackie
Consideration should be given to the use of systemic enzymes to eliminate fibrosis as it is a valid and effective treatment.
In CR 24 on cardiac fibrosis, reference was made to the explanation of the fibrosis connection as a substrate for atrial fibrillation by David Van Wagoner, PhD, researcher in Molecular Cardiology at the Cleveland Clinic. Fibrosis is a long-term response to injury, oxidative stress damage, inflammation and other influences as well. There is abundant support in the literature linking cardiac fibrosis and atrial fibrillation since fibrosis interferes with proper cardiac conduction. (A report as recent as June 2011, suggests that “targeting cardiac fibrosis has potential as a new frontier in anti-arrhythmic therapy”… indicating that cardiac fibrosis management is a logical consideration.) Yet, instead of developing drugs for this purpose, a safe, natural remedy already exists. Systemic enzymes.
The recommendation to reduce various types of fibrosis with systemic or proteolytic enzymes is not new. Practitioners of functional, regenerative or restorative and anti-aging medicine have been using these various enzyme combinations for many years safely and with great success; most importantly, without resorting to invasive surgical procedures.
When I researched the use of the fibrinolytic enzyme, nattokinase, I spent considerable time learning about managing fibrinogen as it relates to blood viscosity. Learning also about systemic enzymes was unavoidable as often they are combined in treatment plans. Audio podcast presentations explaining various applications to eliminate fibrosis by Dr.Wiliam Wong and Dr. Garry Gordon added to the material supplied by enzyme manufacturers along personal interviews with marketers of the Wobenzyme and Vitalzyme people. In one audio, Dr. Wong tells of his wife who had abdominal adhesions from surgery that began to contract so severely she was unable to stand completely upright. To avoid another surgery, he used the enzymes which allowed her to regain her full stature and functionality. He tells of many other patients who were severely impaired by various forms of fibrosis and who were restored to health with systemic enzymes.
I felt comfortable following the guidance of Dr. Wong. As covered in CR 24, and as it turned out, my choice of initially using Vitalzym for almost a year prior to my ablation, most likely helped improve my ablation success, although I was primarily concerned with blood viscosity issues and less aware of the fibrosis factor at the time. In hindsight, the enzymes along with my other heroics undoubtedly were very instrumental in enabling me to progress from having afib every day or every other day, often for 24 – 27 hours, down to zero events for several months prior to ablation.
Wobenzyme was introduced in 1960 in Europe and eventually, reached US practitioners. Wobenzyme Mucos Pharma of Germany provided some of the original data for my initial research as endorsed by Dr. Gordon. Wobenzym N is proven effective by over 160 clinical studies. [
www.mucos.cz] For many years, Dr. Gordon (now in his mid 70’s) has successfully incorporated systemic enzymes into his own protocols and that of his patients.
Dr. Wong worked with World Nutrition (VitalZym) for a number of years and then formulated his own version of what he considers to be a highly effective product based on his hands-on treatment experience.
Dr. William Wong’s credentials:
Texas Complimentary and Alternative Medical Association professional member and World Sports Medicine Hall of Fame member, Dr. William Wong is a Classical Naturopath, a PhD. Exercise Physiologist, Certified Athletic Trainer (AATA), Certified Sports Medicine Trainer (ASMA), Old Rite Catholic Priest and Health/Fitness Consultant.
Dr. Wong has more than 27 years of professional experience in natural health as applied to sports medicine and rehabilitation. The last 8 years of which have been devoted to the application and teaching of Systemic Enzyme Therapy (SET). Studying SET techniques in both the US and Germany, Dr. Wong is widely acknowledged as one of the foremost experts in the field. In the 1990's, he taught Physical Medicine at the South West College of Naturopathic Medicine. In 1993, Dr. Wong was inducted into the Martial Arts Hall of Fame as Wing Chun Kung Fu Instructor of the Year and in 2004, after 37 years in the Martial Arts, he achieved the rank of Grand Master from the Soke (Grand Master's) Council and was awarded a Doctor of Philosophy in Martial Arts.
Dr. Wong has authored books on natural healing and on sports medicine. His shorter writings have appeared in such diverse magazines as G.Q., Black Belt, Survival Guide, The Townsend Letter for Doctors, Well Being Journal, BeautyWalk.com e-zine, and Healthy Options magazine in New Zealand. He has been a guest on over 1000 national and local radio programs, and has appeared on the nationally acclaimed PBS series Healthy Living hosted by Jane Seymour and Heartbeat of America hosted by William Shatner.
Continuing to lecture across the USA, Dr. Wong traveled to India in the Fall of 2005, where he conducted seven different lectures before hundreds of physicians teaching OBGYN's, Plactic Surgeons, Thoracic and General Surgeons, Cardiologists, General Practicioners and Dentists on how to integrate Systemic Enzyme use into Orthodox Medicine.
Currently, Dr. Wong writes books and lectures on anti-aging and pro-sexual topics. He also consults with individuals, specializing in the development of personalized programs for longevity and virility to help people overcome the effects of aging and the after effects of chronic debilitating conditions.
Dr. Gordon is a legend in his own right. One can get lost for days in his collection of audios and YouTube presentations. This article on cardiovascular use of enzymes is one of many.
[
gordonresearch.com]
Garry F. Gordon, MD, DO, MD(H)
President, Gordon Research Institute
www.gordonresearch.com
Dr. Gordon is an internationally recognized expert on chelation therapy and antiaging medicine. He is also a consultant for various supplement companies and the coauthor of The Chelation Answer. He lectures extensively on the topic, The End of Bypass Surgery is in Sight. He is on the board of the Homeopathic Medical Examiners for Arizona, is cofounder of ACAM (American College for Advancement in Medicine) and a board member of the International Oxidative Medicine Association. He received is Doctor of Osteopathy in 1958 from the Chicago College of Osteopathy in Illinois and completed his radiology residency at Mt Zion in San Francisco in 1964. He was the medical director of Mineral Lab in Hayward, CA, a leading laboratory for trace mineral analysis worldwide. He does telephone consultations for patients from around the world offering second opinions on any type of health issue from his offices in Arizona. Dr. Gordon is dedicated and passionate about educating doctors and patients about the harmful and devastating effects of environmental pollution and he provides documented alternatives for any health condition. He wants everyone to feel as good as he does at age seventy-six, having restored himself to optimal health in spite of suffering from serious illnesses for most of the first thirty years of his life including genetic heart disease.
About Vitalzym:
Systemic Enzymes Help You Feel Better, Look Better, and Live Longer
Vitalzym contains potent proteolytic enzymes designed to support health and promote healing and repair. It is an extremely effective systemic enzyme blend with a high Serrapeptase content.
Vitalzym works to break down fibrin in the body. Fibrin is a hard, sticky protein that has been associated with scar tissue, inflammation and pain, among other symptoms and conditions. Additionally, Vitalzym can help reduce viral load and regulate the immune system, reduce toxins and impurities in the blood, promote cellular detoxification, reduce internal inflammation, and promote overall better health.
Enzymes are said to be the “sparks of life.” They are considered keys that can unlock the door to a healthier you because they not only help improve digestion and nutrient absorption; they are also responsible for millions of bodily functions.
Vitalzym works synergistically to provide total system support. It contains protease, serrapeptase, papain, bromelain, amylase, lipase, rutin and amla. According to Dr. Peter Streichhan, a world-renowned enzyme researcher from Germany, "enzyme mixtures have a wider range of therapeutic advantages than do individual enzymes." 1
Continue: [
www.energeticnutrition.com]
My thoughts are:
In light of the role cardiac fibrosis plays in causing arrhythmia, for those afibbers who have supplemented and tested for electrolytes, methylation issues, kidney, adrenal, thyroid, pH etc involvement and still seem unable to achieve NSR, treating with the systemic enzymes seems a reasonable adjunct. Emphasis on using systemic enzymes has not been included regularly or consistently but should be a definite consideration. This will be covered in detail in the fibrosis update report.
As mentioned in another post, the research by Dr. Shivakumar indicates that fibrosis is rooted in magnesium deficiency. Those afibbers who are refractory to magnesium repletion (who seem unable to achieve optimal or sustained intracellular magnesium levels in spite of heroics) are likely caught in the MgD/fibrosis generation web. Eliminating the fibrosis may enable magnesium repletion and/or help facilitate proper conduction without fibrosis interference.
Read more: [
www.afibbers.org]
Magnes Res. 2002 Dec;15(3-4):307-15.
Pro-fibrogenic effects of magnesium deficiency in the cardiovascular system.
Shivakumar K.
Division of Cellular and Molecular Cardiology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram 695 011, India.
shivak@sctimst.ker.nic.in
Magnesium deficiency is known to produce cardiovascular injury. A large body of experimental evidence supports the postulation that an immuno-inflammatory reaction and increased oxidative stress may damage the myocardium and vasculature in magnesium deficiency. Reparative/reactive fibrosis in response to the injury has, however, received little attention. Recent evidence from a rodent model of acute magnesium deficiency suggests that humoral factors may activate cardiac fibroblasts by a free radical-mediated mechanism and contribute to cardiac fibrogenesis. A similar mechanism may also promote cellular hyperplasia and increased matrix synthesis in the vasculature.
Abstract
Magnesium deficiency enhances oxidative stress and collagen synthesis in vivo in the aorta of rats.
Int J Biochem Cell Biol. 1997 Nov;29(11):1273-8.
Shivakumar K1, Kumar BP. [
www.ncbi.nlm.nih.gov]
Antioxidants and Cardiovascular Disease
Ravindra Nath, M. Khullar, Pawan K. Singal
Alpha Science Int'l Ltd., 2004
Chapter Magnesium Deficiency and CV Disease:
Molecular Mechanisms and Recent Advances.
[
books.google.com]
In 2001 Kumar & Shivakumar demonstrated that in hypomagnesia, serum factor may stimulate fibroblast proliferation and net collagen production (deposition) via superoxide-mediated mechanism and contribute to cardiac fibrosis. (clip from Antioxidants and Cardiovascular disease.. p 189)
Invited Review
Journal of Pathology J Pathol 2008; 214:199 – 210
Published online in Wiley InterScience (www.interscience.wiley.com) DOI: 10.1002/path.2277
[
onlinelibrary.wiley.com]
Cellular and molecular mechanisms of fibrosis
TA Wynn*
Immunopathogenesis Section, Laboratory of Parasitic Diseases, National Institute of Allergy and
Infectious Diseases, National Institutes of Health,
Bethesda, MD, USA
No conflicts of interest were declared.
Abstract
Fibrosis is defined by the overgrowth, harden ing, and/or scarring of various tissues and
is attributed to excess deposition of extracellular matrix components including collagen.
Fibrosis is the end result of chronic inflammatory reactions induced by a variety of stimuli
including persistent infections, autoimmune reactions, allergic responses, chemical insults,
radiation, and tissue injury. Although current treatments for fibrotic diseases such as idio-
pathic pulmonary fibrosis, liver cirrhosis, systemic sclerosis, progressive kidney disease,
and cardiovascular fibrosis typically target the inflammatory response, there is accumulat-
ing evidence that the mechanisms driving fibrogenesis are distinct from those regulating
inflammation. In fact, some studies have suggested that ongoing inflammation is needed
to reverse established and progressive fibrosis. The key cellular mediator of fibrosis is
the myofibroblast, which when activated serves as the primary collagen-producing cell.
Myofibroblasts are generated from a variety of sources including resident mesenchymal
cells, epithelial and endothelial cells in processes termed epithelial/endothelial-mesenchymal
(EMT/EndMT) transition, as well as from circulating fibroblast-like cells called fibrocytes
that are derived from bone-marrow stem cells. Myofibroblasts are activated by a variety
of mechanisms, including paracrine signals derived from lymphocytes and macrophages,
autocrine factors secreted by myofibroblasts, and pathogen-associated molecular patterns
(PAMPS) produced by pathogenic organisms that interact with pattern recognition recep-
tors (i.e. TLRs) on fibroblasts. Cytokines (IL-13, IL-21, TGF-β 1), chemokines (MCP-1,
MIP-1 β ), angiogenic factors (VEGF), growth factors (PDGF), peroxisome proliferator-
activated receptors (PPARs), acute phase proteins (SAP), caspases, and components of the
renin–angiotensin–aldosterone system (ANGII) have been identified as important regula-
tors of fibrosis and are being investigated as potential targets of antifibrotic drugs. This
review explores our current understanding of the cellular and molecular mechanisms of
fibrogenesis. Published in 2007 by John Wiley & Sons, Ltd.
See also : David Van Wagoner, PHD [
my.clevelandclinic.org]